Therapeutic applications of sulfamates

Bibliography

• ABBATE F, SUPURAN CT, SCOZZAFAVA A, ORIOLI P, STUBBS MT, KLEBE G: Nonaromatic sulfonamide group as an ideal anchor for potent human carbonic anhydrase inhibitors: role of hydrogen-bonding networks in ligand binding and drug design. J. Med. Chem. (2002) 45:3583–3587.
   PubMed Web of Science ®Google Scholar
• NUSSBAUMER P, BILLICH A: Steroid sulfatase inhibitors. Expert Opin. The]: Patents (2003) 13:605–625.
   Web of Science ®Google Scholar
• SUPURAN CT, SCOZZAFAVA A, CASINI A: Carbonic anhydrase inhibitors. Med. Res. Rev (2003) 23:146–189.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Applications of carbonic anhydrase inhibitors and activators in therapy. Expert Opin. Ther: Patents (2002) 12:217–242.
   Web of Science ®Google Scholar
• SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Tiler. Patents (2000) 10:575–600.
   Web of Science ®Google Scholar
• SCOZZAFAVA A, OWA T, MASTROLORENZO A, SUPURAN CT: Anticancer and antiviral sulfonamides. Carr: Med. Chem. (2003) 10:925–953.
   PubMed Web of Science ®Google Scholar
• WEBER A, CASINI A, HEINE A, KUHN D, SUPURAN CT, SCOZZAFAVA A, KLEBE G: Unexpected nanomolar inhibition of carbonic anhydrase by COX-2 selective celecoidb: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. (2004) 47:550–557.
   PubMed Web of Science ®Google Scholar
• NUSSBAUMER P, BILLICH A: Steroid sulfatase inhibitors. Med. Res. Rev (2004) 24:529–576.
   PubMed Web of Science ®Google Scholar
• WINUM JY, VULLO D, CASINI A, MONTERO J-L, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: inhibition of cytosolic isozymes I and II and the membrane-bound, tumor associated isozyme IX with sulfamates also acting as steroid sulfatase inhibitors. Med. Chem. (2003) 46:2197–2204.
   Web of Science ®Google Scholar
• WINUM JY, VULLO D, CASINI A, MONTERO J-L, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: inhibition of transmembrane, tumor associated isozyme IX and cytosolic isozymes I and II with aliphatic sulfamates. J. Med. Chem. (2003) 46:5471–5477.
   PubMed Web of Science ®Google Scholar
• SPILLANE WJ, RYDER CA, WALSH MR, CURRAN PJ, CONCAGH DG, WALL SN: Sulfamate sweeteners. Food Chem. (1996) 56:255–261.
   Web of Science ®Google Scholar
• SCHIMMEL P, TAO J, HILL J: Aminoacyl tRNA synthetase as targets for new anti-infectives. FASEB J. (1998) 12:1599–1609.
   PubMed Web of Science ®Google Scholar
• VON DER HAAR F, GABIUS H-J, CRAMER F: Target directed drug synthesis: the aminoacyl-tRNA synthetases as possible targets. Angew. Chem. (int. Ed Engl.) (1981) 20:217–223.
   Web of Science ®Google Scholar
• THOMAS SO, SINGLETON VL, LOWERY JA et al.: Nucleocidin, a new antibiotic with activity against Trypanosomes. Antibia Ann. (1956–1957) 1957:716–721.
   Google Scholar
• SHUMAN DA, ROBINS MJ, ROBINS RK: The synthesis of nucleoside sulfamates related to nucleocidin. J. Am. Chem. Soc. (1970) 92:3434–3437.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI E, BEPPU T: A new nucleosidic antibiotic AT-265. J. Antibia (1982) 35:939–947.
   PubMed Web of Science ®Google Scholar
• KINI GD, HENRY EM, ROBINS RK et al.: Synthesis, structure and antiparasitic activity of sulfamoyl derivatives of Ribavirin. J. Med. Chem. (1990) 33:44–48.
   PubMed Web of Science ®Google Scholar
• PETERSON EM, BROWNELL J, VINCE R: Synthesis and biological evaluation of Y-sulfamoylated purinyl carbocyclic nucleosides. Med. Chem. (1992) 35:3991–4000.
   Web of Science ®Google Scholar
• BLOCK A, COUTSOGEORGOPOULOS C: Inhibition of protein synthesis by 5'-sulfamoyladenosine. Biochemistry (1971) 10:4394–4398.
   Web of Science ®Google Scholar
• GUAY DR: Treatment of bacterial skin and skin structure infection. Expert Opin. Pharmacother. (2003) 4:1259–1275.
   PubMed Web of Science ®Google Scholar
• UEDA H, SHOKU Y, HAYASHI N et at.: X-ray crystallographic conformational study of 5'- 0-[N- (L-alany1)-sulfamoyl]adenosine, a substrate analogue for alanyl-tRNA synthetase. Biochim. Biophys. Acta (1991) 1080:126–134.
   Google Scholar
• FORREST AK, JARVEST RL, MENSAH LM, O'HANLON PJ, POPE AJ, SHEPPARD RJ: Aminoalkyl adenylate and aminoacyl sulfamate intermediate analogues differing greatly in affinity for their cognate Staphylococcus aureus aminoacyl tRNA synthetases. Bioorg. Med. Chem. Lett. (2000) 10:1871–1874.
   PubMed Web of Science ®Google Scholar
• BROWN MJB, MENSAH LM, DOYLE ML et al.: Rational design of femtomolar inhibitors of isoleucyl tRNA synthetase from a binding model for pseudomonic acid-A. Biochemistry (2000) 39:6003–6011.
   PubMed Web of Science ®Google Scholar
• HEACOCK D, FORSYTH CJ, KIYOTAKA S, MUSIER-FORSYTH K: Synthesis and aminoacyl-tRNA synthetase inhibitory activity of prolyl adenylate analogs. Bioorg. Chem. (1996) 24:273–289.
   Web of Science ®Google Scholar
• BELRHALI H, YAMENCHUK A, TUKALO M et al.: Crystal structures at 2.5 A resolution of seryl-tRNA synthetase complexed with two analogs of seryl adenylate. Science (1994) 263:1432–1436.
   Google Scholar
• BROWN P, RICHARDSON CM, MENSAH LM et al.: Molecular recognition of tyrosinyl adenylate analogues by prokaryotic tyrosyl tRNA synthetases. Bioorg. Med. Chem. (1999) 7:2473–2485.
   PubMed Web of Science ®Google Scholar
• LEE J, KIM SE, LEE JY et al.: N -Alkoxysulfamide, N-hydroxysulfamide, and sulfamate analogues of methionyl and isoleucyl adenylates as inhibitors of methionyl-tRNA synthetases. Bioorg. Med. Chem. Lett. (2003) 13:1087–1092.
   PubMed Web of Science ®Google Scholar
• ISONO K, URAMOTO M, KUSAKABE H et al.: Ascamycin and dealanylascamycin, nucleoside antibiotics from Streptomyces sp. J. Antibia (1984) 37:670–672.
   PubMed Web of Science ®Google Scholar
• OSADA H, ISONO K: Mechanism of action and selective toxicity of ascamycin, a nucleoside antibiotic. Antimicrob. Agents Chemother: (1985) 27:230–233.
   PubMed Web of Science ®Google Scholar
• YU XY, HILL JM, YU G, WANG W, KLUGE AF, WENDLER P, GALLANT P: Synthesis and structure-activity relationships of a series of novel thiazoles as inhibitors of aminoacyl-tRNA synthetases. Bioorg. Med. Chem. Lett. (1999) 9:375–380.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT, INNOCENTI A, MASTROLORENZO A, SCOZZAFAVA A: Antiviral sulfonamide derivatives. Mini-Rev Med. Chem. (2004) 4:189–200.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Highlights in the development of new antiviral agents. Mini Rev Med. Chem. (2002) 2:163–175.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: New anti-HIV agents and targets. Med. Res. Rev. (2002) 22:531–565.
   PubMed Web of Science ®Google Scholar
• DE CLERCQ E: Strategies in the design of antiviral drugs. Nat. Rev Drug army. (2002) 1:13–25.
   PubMed Web of Science ®Google Scholar
• RICHMAN DD: HIV chemotherapy. Nature (2001) 410:995–1001.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT, CASINI A, SCOZZAFAVA A: Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents. Med. Res. Rev (2003) 23:535–558.
   PubMed Web of Science ®Google Scholar
• SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Non-pepc chemokine receptors antagonists as emerging anti-HIV agents. Enzyme Inhib. Med. Chem. (2002) 17:69–76.
   PubMed Web of Science ®Google Scholar
• MASTROLORENZO A, SCOZZAFAVA A, SUPURAN CT: Small-molecule antagonists of chemokine receptors as emerging anti-HIV agents. Expert Opin. The]: Patents (2001) 11:1245–1252.
   Web of Science ®Google Scholar
• VINCE R, PHAM P: The synthesis and biological evaluation of sulfamoyl nucleosides related to carbovir and AZT. Nucleos. Nucleot. (1995) 14:2051–2060.
   Google Scholar
• JENNINGS LJ, MACCHIA M, PARKIN A: Synthesis of analogues of 5-iodo-2'-deoxyuridine-Y-diphosphate. Chem. Soc., Perkin Trans. I (1992):2197–2202.
   Google Scholar
• CAMARASA MJ, FERNANDEZ-RESA P, GARCIA-LOPEZ MT et al.: Uridine Y-diphosphate glucose analogues. Inhibitors of protein glycosylation that show antiviral activity. I Med. Chem. (1985) 28:40–46.
   Google Scholar
• FERNANDEZ-RESA P, GARCIA -LOPEZ MT, DE LAS HERAS F, SAN FELIX A, ALARCON B, CARRASCO L: Diphosphate modified antiviral analogues of uridine Y-diphosphate glucose derivatives. Ear: J. Med. Chem. (1986) 21:245–249.
   Web of Science ®Google Scholar
• FIANDOR J, GARCIA-LOPEZ MT, DE LAS HERAS F et al.: Hexose-modified anti-viral analogues of uridine Y-diphosphate glucose derivatives. Ear: J. Med. Chem. (1986) 22:59–65.
   Google Scholar
• PEREZ-PEREZ MJ, BALZARINI J, DE CLERCQ E, CAMARASA MJ: Glycosyl-oxycarbonylaminosulfonyl-2',3'-dideoxynucleoside derivatives as lipophilic nucleotide mimics. Synthesis and anti-HIV activity. Bioorg. Med. Chem. (1993) 1:279–284.
   Google Scholar
• VARA PRASAD JVN, MARKOSKI LJ, BOYER FE et al.: Nonpeptidic HIV protease inhibitors: 6-alky1-5,6-dihydropyran-2-ones possessing a novel and achiral 3 (2 t butyl 5 methy1-4-sulfamate)phenylthio moiety. Bioorg. Med. Chem. Lett. (1999) 9:2217–2222.
   PubMed Web of Science ®Google Scholar
• BARBARO G, SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Carr: Pharm. Des. (2004) in press.
   Google Scholar
• HERNANDEZ-GUZMAN FG, HIGASHIYAMA T, PANGBORN W, OSAWA Y, GHOSH D: Structure of human estrone sulfatase suggests functional roles of membrane association. " Biol. Chem. (2003) 278:22989–22997.
   PubMed Web of Science ®Google Scholar
• POIRIER D, CIOBANU LC, MALTAIS R: Steroid sulfatase inhibitors. Expert Opin. Ther. Patents (1999) 9:1083–1099.
   Web of Science ®Google Scholar
• SMITH HJ, NICHOLLS PJ, SIMONS C, LE LAIN R: Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers. Expert Opin. Thec Patents (2001) 11:789–824.
   Web of Science ®Google Scholar
• AHMED S, JAMES K, OWEN CP, SAMPSON L, PATEL CK: Review of estrone sulfatase and its inhibitors-an important new target against hormone dependent breast cancer. Can: Med. Chem. (2002) 9:263–273.
   PubMed Web of Science ®Google Scholar
• PUROHIT A, WOO LW, CHANDER SK et al.: Steroid sulphatase inhibitors for breast cancer therapy.' Steroid Biochem. Ma Biol. (2003) 86:423–432.
   PubMed Web of Science ®Google Scholar
• HOWARTH NM, PUROHIT A, REED MJ, POTTER BVL: Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential. " Med. Chem. (1994) 37:219–221.
   PubMed Web of Science ®Google Scholar
• BILLICH A, ROTA, LAM C, SCHMIDT JB, SCHUSTER I: Immunohistochemical localization of steroid sulfatase in acne lesions: Implications for the contribution of dehydroepiandrosterone sulfate to the pathogenesis of acne. Holm. Res. (2000) 532:92–103.
   Google Scholar
• CHEN W, THIBOUTOT D, ZOUBOULIS CC: Cutaneous androgen metabolism: basic research and clinical perspectives.' Invest. Dermatol (2002) 119:992–1007.
   PubMed Web of Science ®Google Scholar
• WOLF OT, KIRSCHBAUM C: Actions of dehydroepiandrosterone and its sulfate in central nervous system: effect on cognition and emotion in animals and humans. Brain Res. Rev (1999) 30:264–288.
   PubMedGoogle Scholar
• SUITTERS AJ, SHAW S, WALES MR et al.: Immune enhancing effects of dehydroepiandrosterone and dehydroepiandrosterone sulphate and the role of steroid sulfatase. Immunology (1997) 91:314–321.
   PubMed Web of Science ®Google Scholar
• AHMED S, JAMES K, OWEN CP, PATEL CK, PATEL M: Acid dissociation constant, a potential physicochemical factor in the inhibition of the enzyme estrone sulfatase (ES). Bioorg. Med. Chem. Lett. (2001) 11:899–902.
   PubMed Web of Science ®Google Scholar
• AHMED S, JAMES K, OWEN CP, PATEL CK, SAMPSON L: The mechanism of irreversible inhibition of estrone sulfatase (ES) through the consideration of a range of methane- and amino-sulfonate-based compounds. Bioorg. Med. Chem. Lett. (2002) 12:1279–1282.
   PubMed Web of Science ®Google Scholar
• AHMED S, OWEN CP, JAMES K, PATEL CK, PATEL M: Novel inhibitors of the enzyme estrone sulfatase (ES). Bioorg. Med. Chem. Lett. (2001) 11:841–844.
   PubMed Web of Science ®Google Scholar
• AHMED S, JAMES K, OWEN CP, PATEL CK, PATEL M: Hydrophobicity, a physicochemical factor in the inhibition of the enzyme estrone sulfatase (ES). Bioorg. Med. Chem. Lett. (2001) 11:2525–2528.
   Google Scholar
• PATEL CK, OWEN CP, AHMED S: The design, synthesis, and M vitro biochemical evaluation of a series of esters of 4- [(aminosulfonyl)oxy]benzoate as novel and highly potent inhibitors of estrone sulfatase. Biochem. Biophys. Res. Commun. (2003) 307:778–781.
   PubMed Web of Science ®Google Scholar
• PATEL CK, OWEN CP, AHMED S: Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg. Med. Chem. Lett. (2004) 14:605–609.
   PubMed Web of Science ®Google Scholar
• NUSSBAUMER P, BILBAN M, BILLICH A: 4, 4'-Benzophenone- 0, C-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg. Med. Chem. Lett. (2002) 12:2093–2095.
   PubMed Web of Science ®Google Scholar
• AHMED S, JAMES K, OWEN CP, PATEL CK: Design, synthesis and biochemical evaluation of AC ring mimics s novel inhibitors of the enzyme estrone sulfatase. Bioorg. Med. Chem. Lett. (2002) 12:1343–1346.
   PubMed Web of Science ®Google Scholar
• OKADA M, NAKAGAWA T, IWASHITA S, TAKEGAWA S, FUJII T, KOIZUMI N: Development of novel steroid sulfatase inhibitors. I. Synthesis and biological evaluation of biphenyl-4-0-sulfamates. I Steroid Biochem. Ma Biol. (2003) 87:141–148.
   PubMed Web of Science ®Google Scholar
• SAITO T, KINOSHITA S, FUJII T et al.:Development of novel steroid sulfatase inhibitors. II. TZS-8478 potently inhibits the growth of breast tumors in postmenopausal breast cancer model rats. Steroid Biochem. Ma Biol. (20 0 4) in press.
   Google Scholar
• LI PK, MILANO S, KLUTH L, RHODES ME: Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors. Steroid Biochem. Ma Biol. (1996) 59:41–48.
   PubMed Web of Science ®Google Scholar
• KOLLI A, CHU GH, RHOSED ME, INOUE K, SELCER KW, LI PK: Development of (p-O-sulfamoyfl-N-alkanoyl-phenylalkyl amines as non-steroidal estrone sulfatase inhibitors. Steroid Biochem. Ma Biol. (1999) 68:31–40.
   PubMed Web of Science ®Google Scholar
• CIOBANU LC, LUU-THE V, POIRIER D: Non-steroidal compounds designed to mimic potent steroid sulfatase inhibitors. Steroid Biochem. Ma Biol. (2002) 80:339–353.
   PubMed Web of Science ®Google Scholar
• AHMED S, JAMES K, MASTRI C, ROWLANDS MG: Dual inhibitors - synthesis and evaluation of novel inhibitors of the enzymes aromatase and oestrone sulphatase, a novel therapeutic approach. Pharm. Pharmacol. (1999) 51S:255.
   Google Scholar
• WOO LW, SUTCLIFFE OB, BUBERT C et al.: First dual aromatase-steroid sulfatase inhibitors. Med. Chem. (2003) 46:3193–3196.
   Web of Science ®Google Scholar
• GOLOB T, LIEBL R, VON ANGERER E:Sulfamoyloxy-substituted 2-phenylindoles: antiestrogen-based inhibitors of the steroid sulfatase in human breast cancer cells. Bioorg. Med. Chem. (2002) 10:3941–3953.
   PubMed Web of Science ®Google Scholar
• CHU GH, PETERS A, SELCER KW, LI PK: Synthesis and sulfatase inhibitory activities of (4- and (4-4-hydroxytamoxifen sulfamates. Bioorg. Med. Chem. Lett. (1999) 9:141–144.
   PubMed Web of Science ®Google Scholar
• WOO LWL, PUROHIT A, MALINI B, REED MJ, POTTER BV: Potent active site-directed inhibition of steroid sulphatase by tricyclic coumarin-based sulphamates. Chem. Biol. (2000) 7:773–791.
   PubMedGoogle Scholar
• MALINI B, PUROHIT A, GANESHAPILLAI D, WOO LW, POTTER BV, REED MJ: Inhibition of steroid sulphatase activity by tricyclic coumarin sulphamates.J. Steroid Biochem. Ma Biol. (2000) 75:253–258.
   PubMed Web of Science ®Google Scholar
• PUROHIT A, WOO LWL, BARROW D et al.: Non-steroidal and steroidal sulfamates: new drugs for cancer therapy. Ma Cell Endocrina (2001) 171:129–135.
   PubMed Web of Science ®Google Scholar
• NUSSBAUMER P, LEHR P, BILLICH A:2-Substituted 4-(thio)chromenone 6-0-sulfamates: potent inhibitors of human steroid sulfatase. Med. Chem. (2002) 45:4310–4320.
   Web of Science ®Google Scholar
• NUSSBAUMER P, WINISKI AP, BILLICH A: Estrogenic potential of 2-alkyl-4-(thio)chromenone 6-0-sulfamates: potent inhibitors of human steroid sulfatase. Med. Chem. (2003) 46:5091–5094.
   Web of Science ®Google Scholar
• SCHREINER: EE WOLFF B, WINISKI AEBILLICH A: 6-(2-adamantan-2-ylidene-hydroxybenzoxazole)-0-sulfamate: a potent non-steroidal irreversible inhibitor of human steroid sulfatase. Bioorg. Med. Chem. Lett. (2003) 13:4313–4316.
   PubMed Web of Science ®Google Scholar
• BILBAN M, BILLICH A, AUER M, NUSSBAUMER P: New fluorogenic substrate for the first continuous steroid sulfatase assay. Bioorg. Med. Chem. Lett. (2000) 10:967–969.
   PubMed Web of Science ®Google Scholar
• PUROHIT A, VERNON KA, WAGENAAR -HUMMELINCK AE et al.: The development of A ring modified analogues of oestrone-3-0-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. Steroid Biochem. Ma Biol. (1998) 64:269–275.
   Google Scholar
• REED JE, WOO LWL, ROBINSON JJ et al.: 2-Difluoromethylestrone 3-0-sulphamate, a highly potent steroid sulphatase inhibitor. Biochem. Biophys. Res. Commun. (2004) 317:169–175.
   PubMed Web of Science ®Google Scholar
• ELGER W, SCHWARZ S, HEDDEN A, REDDERSEN G, SCHNEIDER B: Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application. Steroid Biochem. Ma Biol. (1995) 55:395–403.
   PubMed Web of Science ®Google Scholar
• SUZUKI RN, NEWMAN SP, PUROHIT A, LEESE MP, POTTER BV, REED MJ: Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyoestradiol-bis-sulphamate and 2-ethyloestradiol-bis-sulphamate. Steroid Biochem. Ma Biol. (2003) 84:269–278.
   PubMed Web of Science ®Google Scholar
• HEJAZ HA, PUROHIT A, MAHON ME REED MJ, POTTER BV: Synthesis and biological activity of the superestrogen 1 7-oximino-3-0-sulfamoy1-1,3,5 (10)-estratriene: X-ray crystal structure of (h)-17-oximino-3-hydroxy-1,3,5 (10) -estratriene. Med . Chem. (1999) 42:3188–3192.
   Web of Science ®Google Scholar
• LI PK, CHU GH, GUO JP, PETERS A, SELCER KW: Development of potent non-estrogenic estrone sulfatase inhibitors. Steroids (1998) 63:425–432.
   PubMed Web of Science ®Google Scholar
• CIOBANU LC, BOIVIN RP, LUU -THE V, LABRIE F, POIRIER D: Potent inhibition of steroid sulfatase activity by 3-0-sulfamate 1 7a-benzyl (or 4' - tert-butylbenzy9 estra-1,3,5 (10)-trienes: combination of two substituents at positions C3 and C17a of estradiol. J. Med. Chem. (1999) 42:2280–2286.
   PubMed Web of Science ®Google Scholar
• FISCHER DS, CHANDER SK, WOO LW et al.: Novel D-ring modified steroid derivatives as potent, non-estrogenic, steroid sulfatase inhibitors with in vivo activity. Steroid Biochem. Ma Biol. (2003) 84:343–349.
   PubMed Web of Science ®Google Scholar
• FISCHER DS, WOO LW, MAHON ME PUROHIT A, REED MJ, POTTER BV: D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase. Bioorg. Med. Chem. (2003) 11:1685–1700.
   PubMed Web of Science ®Google Scholar
• CIOBANU LC, POIRIER D: Solid-phase parallel synthesis of 17a-substituted estradiol sulfamate and phenol libraries using the multidetachable sulfamate linker. Comb . Chem. (2003) 5:429–440.
   PubMedGoogle Scholar
• RODIG H, BRUST P, ROMER J et al.: Distribution of estrone sulfatase in rat brain determined by in vitro autoradiography with 16alpha-r8F1fluoroestradiol-3,1713-disulfamate. Appl. Radiat. Isot. (2002) 56:773–780.
   PubMed Web of Science ®Google Scholar
• BRUST P, RODIG H, ROMER J et al.: Distribution of 16a- P8F1fluoro-estradiol-3,1713-disulfamate in rats, tumour-bearing mice and piglets. Appl. Radiat. [sot. (2002) 57:687–695.
   PubMed Web of Science ®Google Scholar
• TRIPP BC, BELL CB 3RD, CRUZ F, KREBS C, FERRY JG: A role for iron in an ancient carbonic anhydrase. Biol. Chem. (2004) 279:6683–6687.
   Web of Science ®Google Scholar
• LANE TW, MOREL FM: A biological function for cadmium in marine diatoms. Proc. Nati Acad. Sri. USA (2000) 97:4627–4631.
   PubMed Web of Science ®Google Scholar
• SOAK, ESPIE GS, WILLIAMS EB, SHIVELY JM, HEINHORST S, CANNON GC: A novel evolutionary lineage of carbonic anhydrase (epsilon class) is a component of the carboxysome shell. Bacteria (2004) 186:623–630.
   PubMed Web of Science ®Google Scholar
• LEHTONENJ, SHEN B, VIHINEN M et al.: Characterization of CA XIII, a novel member of the carbonic anhydrase isozyme family. J. Biol Chem. (2004) 279:2719–2727.
   PubMed Web of Science ®Google Scholar
• PASTOREKOVA S, PARKKILA S, PASTOREK J, SUPURAN CT: Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. I Enz. Inhib. Med. Chem. (2004) 19:199–229.
   PubMed Web of Science ®Google Scholar
• Carbonic Anhydrate - Its Inhibitors And Activators. Supuran CT, Scozzafava A, Conway J (Eds). CRC Press, Boca Raton, FL, USA (2004):1–376.
   Google Scholar
• SUPURAN CT: Indisulam: an anticancer sulfonamide in clinical development. Expert Opin. Investig. Drugs (2003) 12:283–287.
   PubMed Web of Science ®Google Scholar
• ABBATE F, CASINI A, OWA T, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. (2004) 14:217–223.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT: Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin. Thar. Patents (2003) 13:1545–1550.
   Web of Science ®Google Scholar
• LO YS, NOLAN JC, MAREN TH, WELSTEAD WJ, GRIPSHOVER DF, SHAMBLEE DA: Synthesis and physicochemical properties of sulfamate derivatives as topical antiglaucoma agents. Med . Chem. (1992) 35:4790–4794.
   Web of Science ®Google Scholar
• BRIGANTI F, PIERATTELLI R, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors. Part 37. Novel classes of carbonic anhydrase inhibitors and their interaction with the native and cobalt-substituted enzyme: kinetic and spectroscopic investigations. Eur.j Med. Chem. (1996) 31:1001–1010.
   Google Scholar
• MARYANOFF BE, NORTEY SO, GARDOCKI JF, SHANK RP, DODGSON SP: Anticonvulsant 0-alkyl sulfamates. 2,3:4,5-Bis- 041-methylethylidene)-P-D-fructopyranose sulfamate and related compounds. Med. Chem. (1987) 30:880–887.
   Google Scholar
• MARYANOFF BE, COSTANZO MJ, NORTEY SO et al.: Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.' Med. Chem. (1998) 41:1315–1343.
   PubMed Web of Science ®Google Scholar
• RECACHA R, COSTANZO MJ, MARYANOFF BE, CHATTOPADHYAY D: Crystal structure of human carbonic anhydrase II complexed with an anti-convulsant sugar sulphamate. Biochem. (2002) 361:437–441.
   Google Scholar
• CASINI A, ANTEL J, ABBATE F et al.: Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV. Bioorg. Med. Chem. Lett. (2003) 13:841–845.
   PubMed Web of Science ®Google Scholar
• ANTEL J, WEBER A, SOTRIFFER CA, KLEBE G: Multiple binding modes observed in X-ray structures of carbonic anhydrase-inhibitor complexes and elsewhere: consequences for structure-based drug design. In: Carbonic Anhydrase - Its Inhibitors And Activators. Supuran CT, Scozzafava A, Conway J (Eds). CRC Press, Boca Raton, FL, USA (2004):45–66.
   Google Scholar
• VICKER N, HO Y, ROBINSON J et al.: Docking studies of sulphamate inhibitors of estrone sulphatase in human carbonic anhydrase II. Bioorg. Med. Chem. Lett. (2003) 13:863–865.
   PubMed Web of Science ®Google Scholar
• HO YT, PUROHIT A, VICKER N et al. Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates. Biochem. Biophys. Res. Commun. (2003) 305:909–914.
   PubMed Web of Science ®Google Scholar
• ABBATE F, WINUM JY, POTTER BV et al.: Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. Bioorg. Med. Chem. Lett. (2004) 14:231–234.
   PubMed Web of Science ®Google Scholar
• PASTOREKOVA S, PASTOREKJ: Cancer-related carbonic anhydrase isozymes. In: Carbonic anhydrase - Its inhibitors and activators Supuran CT, Scozzafava A, Conway J (Eds) CRC Press, Boca Raton, FL, USA (2004):253–280.
   Google Scholar
• MASEREEL B, ROLIN S, ABBATE F, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. Med. Chem. (2002) 45:312–320.
   Web of Science ®Google Scholar
• ILIES MA, MASEREEL B, ROLIN S et al.: Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity. Bioorg . Med. Chem. (2004) 12:2717–2726.
   PubMed Web of Science ®Google Scholar
• SHANK RP, GARDOCKI JF, VAUGHT JL et al.: Topiramate: preclinical evaluation of structurally novel anticonvulsant. Epilepsia (1994) 35:450–460.
   PubMed Web of Science ®Google Scholar
• SILLS GJ, LEACH JP, KILPATRICK WS, FRASER CM, THOMPSON GG, BRODIE MJ: Concentration-effect studies with topiramate on selected enzymes and intermediates of the GABA shunt. Epilepsia (2000) 41:S30–S34.
   Web of Science ®Google Scholar
• ROSENFELD WE: Topiramate: a review of preclinical, pharmacokinetic, and clinical data. Clin. Thar (1997) 19:1294–1308.
   PubMed Web of Science ®Google Scholar
• HERRERO Al, DEL OLMO N, GONZALEZ-ESCALADA JR, SOLIS JM: Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacol (2002) 42:210–220.
   PubMed Web of Science ®Google Scholar
• KUZNIECKY R, HO S, PAN J et al.: Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology (2002) 58:368–372.
   PubMed Web of Science ®Google Scholar
• REIS J, TERGAU F, HAMER HM et al.: Topiramate selectively decreases intracortical excitability in human motor cortex. Epilepsia (2002) 43:1149–1156.
   PubMed Web of Science ®Google Scholar
• GIBBS JVV III, SOMBATI S, DELORENZO RJ, COULTER DA: Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia (2000) 41:S10–516.
   Web of Science ®Google Scholar
• SKRADSKI S, WHITE HS: Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia (2000) 41:S45–S47.
   Web of Science ®Google Scholar
• ZULLINO DF, KRENZ S, BESSON J: AMPA blockade may be the mechanism underlying the efficacy of topiramate in PTSD. Clin. Psych. (2003) 64:219–220.
   Web of Science ®Google Scholar
• MCLEAN MJ, BUKHARI AA, WAMIL AW: Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia (2000) 41:S21–S24.
   Web of Science ®Google Scholar
• TAVERNA S, SANCINI G, MANTEGAZZA M, FRANCESCHETTI S, AVANZINI G: Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. Pharmacol Exp. Ther. (1999) 288:960–968.
   PubMed Web of Science ®Google Scholar
• PERUCCA E: A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res. (1997) 35:241–256.
   PubMed Web of Science ®Google Scholar
• DODGSON SJ, SHANK RP, MARYANOFF BE: Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia (2000) 41:S35–S39.
   Web of Science ®Google Scholar
• FAKHOURY T, MURRAY L, SEGER D, MCLEAN M, ABOU-KHALIL B: Topiramate overdose: clinical and laboratory features. Epilepsy Behav (2002) 3:185–189.
   PubMed Web of Science ®Google Scholar
• KUO RL, MORAN ME, KIM DH, ABRAHAMS HM, WHITE MD, LINGEMAN JE: Topiramate-induced nephrolithiasis. Endourol (2002) 16:229–231.
   PubMed Web of Science ®Google Scholar
• RIBACOBA-MONTERO R, SALAS -PUIG X: Efficacy and tolerability of long term topiramate in drug resistant epilepsy in adults. Rev Neural. (2002) 34:101–105.
   PubMed Web of Science ®Google Scholar
• ARIBI AM, STRINGER JL: Effects of antiepileptic drugs on extracellular pH regulation in the hippocampal CA1 region in viva Epilepsy Res. (2002) 49:143–151.
   Google Scholar
• STRINGER JL: A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat. Epilepsy Res. (2000) 40:147–153.
   PubMed Web of Science ®Google Scholar
• HAZEN SA, WAHEED A, SLY WS, LANOUE KF, LYNCH CJ: Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes. FASEB J. (1996) 10:481–490.
   PubMed Web of Science ®Google Scholar
• LYNCH CJ, FOX H, HAZEN SA, STANLEY BA, DODGSON SJ, LANOUE KF: Role of hepatic carbonic anhydrase in de novo lipogenesis. Biochem. (1995) 310:197–202.
   Web of Science ®Google Scholar
• GORDON A, PRICE.H: Mood stabilization and weight loss with topiramate. Am. J. Psychiatry (1999) 156:968–969.
   Web of Science ®Google Scholar
• PICARD F, DESHAIES Y, LALONDE J, SAMSON P, RICHARD D: Topiramate reduces energy and fat gains in lean (Fan) and obese (fa/fa) Zucker rats. Obesity Res. (2000) 8:656–663.
   PubMedGoogle Scholar
• VULLO D, FRANCHI M, GALLORI E, ANTEL J, SCOZZAFAVA A, SUPURAN CT: Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. Med. Chem (2004) 47: 12 7 2–1 279 .
   Google Scholar
• SLISKOVIC DR, KRAUSE BR, PICARD JA et at Inhibitors of Acyl-CoA: cholesterol 0-acyltransferase (ACAT) as hypocholesterolemic agents. The first water-soluble ACAT inhibitor with lipid-regulating activity. J. Med. Chem. (1994) 37:560–562.
   Google Scholar
• LEE HT, SLISKOVIC DR, PICARD JA et al.: Inhibitors of Acyl-CoA: cholesterol 0-acyltransferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. Med. Chem. (1996) 39:5031–5034.
   Google Scholar
• LLAVERIAS G, LAGUNA JC, ALEGRET M: Pharmacology of the ACAT inhibitor avasimibe (CI-1011). Cardiovasc. Drug Rev (2003) 1:33–50.
   Google Scholar
• BURNETT JR, HUFF MW: Avasimibe Pfizer. Carr. Opin. Investig. Drugs (2002) 3:1328–1333.
   PubMedGoogle Scholar
• WALSH DA, LO YS, SHAMBLEE DA, WELSTEAD WJ, NOLAN JC, GRAFF G: Methylsulfamic acid esters. A new chemical class of oral antiarthritic agents. J. Med. Chem. (1990) 33:2068–2070.
   Google Scholar
• NOLAN JC, WALSH DA, LO Y et al: AHR- 15010: a novel anti-arthritic agent. Pharm. Pharmacol. (1990) 42:533–537.
   PubMed Web of Science ®Google Scholar